As part of its ongoing commitment to progressing cancer research, Pfizer has announced that it will collaborate with Breast Cancer Now as part of its Europe-wide Breast Cancer Now Catalyst Programme.
Pfizer is the first to collaborate with Breast Cancer Now on this new breast cancer research programme.
The programme is based on a collaborative approach to research, bringing together the industry, researchers and funders to accelerate the development of treatments to support Breast Cancer Now’s goal of stopping breast cancer deaths by 2050.
Pfizer’s commitment includes allowing academic researchers access to certain drugs in Pfizer’s oncology pipeline, opening up some of its existing and experimental medicines to independent research. Pfizer has also committed around £10 million over three years, to fund research proposed as part of the programme.
The programme will allow the scientific community to propose research projects based on their unique insights into patient needs and understanding of cancer therapies.
Proposals will be reviewed by an independent steering committee, with the successful proposals receiving funding and access to Pfizer’s oncology portfolio.
Rob Day, Head of Pfizer Oncology UK, commented, ‘Like Breast Cancer Now our aim is to improve the outlook for people living with cancer and we will continue to work hard to develop medicines that control and cure people’s cancer. We firmly believe that through collaborations, such as this, we can achieve more and move faster.
We’ve made huge strides in understanding and treating cancer already and that knowledge is only continuing to grow and advance through collaboration.’
